CanaQuest Announces Key Appointments to Team to Drive CQ-001 through Clinical Trials
11. Juni 2024 09:00 ET
|
CanaQuest Medical Corp.
Appointee, formerly with GW Pharma (subsidiary), brings extensive expertise in cannabinoid therapeutics, including the FDA-approved launch of cannabidiol (Epidiolex®) TORONTO, ON, June 11, 2024 ...
CANAQUEST SIGNS MEDICINAL CANNABIS EDUCATION PARTNERSHIP WITH THE CANADIAN CANNABIS DISPUTE RESOLUTION CENTRE
11. März 2021 09:00 ET
|
CanaQuest Medical Corp
TORONTO, March 11, 2021 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing...
CANAQUEST SIGNS MENTANINE® AND MENTABINOL® PRODUCTION AND DISTRIBUTION AGREEMENT WITH PURCANN PHARMA AND SILICYCLE INC.
02. Februar 2021 09:00 ET
|
CanaQuest Medical Corp
TORONTO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing...
CANAQUEST ANNOUNCES MENTABINOL® A SCIENTIFIC DISCOVERY, AS PUBLISHED IN THE JOURNAL OF NEUROSCIENCE
03. Dezember 2020 09:00 ET
|
CanaQuest Medical Corp
TORONTO, Dec. 03, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing...
UPDATE: CANAQUEST MEDICAL CORP FILES PROVISIONAL PATENT FOR MENTANINE® - OMEGA-3 & PURE CANNABIDIOL (“CBD”) FORMULATION BOOSTING MENTAL HEALTH EFFICACY WHILE MINIMIZING CBD DOSAGE
14. Juli 2020 11:04 ET
|
CanaQuest Medical Corp
TORONTO, July 14, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a company developing unique health products and nutraceuticals utilizing...
CANAQUEST MEDICAL CORP announces filing of INTERNATIONAL CANNABIS PATENT
17. September 2019 09:00 ET
|
CanaQuest Medical Corp
A NOVEL BOTANICAL AND TETRAHYDROCANNABINOL (“THC”) FORMULATION FOR THE REDUCTION OF CANNABIS-INDUCED NEGATIVE NEUROPSYCHIATRIC SIDE-EFFECTS Research & development a primary focus for this medical...
CANAQUEST MEDICAL CORP announces filing of CANNABIS/BOTANICAL PROVISIONAL PATENTS
05. Februar 2019 09:30 ET
|
CanaQuest Medical Corp
UNIQUE BOTANICAL AND TETRAHYDROCANNABINOL (“THC’) FORMULATION TREATING PSYCHIATRIC DISORDERS WITHOUT THE NEGATIVE PSYCHIATRIC SIDE-EFFECTS OF THC TORONTO, Feb. 05, 2019 (GLOBE NEWSWIRE) -- ...
Algae Dynamics Corp Changing Name To CanaQuest Medical Corp
28. Januar 2019 13:32 ET
|
Algae Dynamics Corporation
TORONTO, Jan. 28, 2019 (GLOBE NEWSWIRE) -- ALGAE DYNAMICS CORP (OTC: “ADYNF”) (the "Company"), a company focused on the development of unique health products and nutraceuticals utilizing cannabis...